Published in final edited form as:

Chem Commun (Camb). 2014 February 18; 50(14): 1691–1693. doi:10.1039/c3cc48132h.

Enzyme-triggered Gelation: Targeting Proteases with Internal Cleavage Sites

Steven C. Bremmer^{a,b}, Anne J. McNeil^a, and Matthew B. Soellner^b

Anne J. McNeil: ajmcneil@umich.edu; Matthew B. Soellner: soellner@med.umich.edu

^aDepartment of Chemistry and Macromolecular Science and Engineering Program, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan, 48109-1055, USA

^bDepartments of Chemistry and Medicinal Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan, 48109-1055, USA

Abstract

A generalizable method for detecting protease activity via gelation is described. A recognition sequence is used to target the protease of interest while a second protease is used to remove the residual residues from the gelator scaffold. Using this approach, selective assays for both MMP-9 and PSA are demonstrated.

Because both overexpressed and overactive enzymes correlate with disease, simple visual assays that respond to enzymatic activity are in high demand.¹ Colorimetric and fluorimetric assays dominate the field,² but the analysis can be challenging in the complex medium of biological fluids. An alternative approach is to use an enzyme to trigger a phase transition (e.g., solution-to-gel) by cleaving a covalent bond.³ Such assays can be performed in media as complex as blood or cells, and the results are unambiguously detected without any instrumentation. In 2004, Xu and coworkers reported the first enzyme-mediated gelation of small molecules.⁴ Since then, several different enzymes have been used to trigger gelation.⁵

Though promising, only a handful of reported enzyme-triggered gelations are selective for a single enzyme.⁶ Most of these selective systems use peptide-based recognition sequences. Enzymatic cleavage at the N-terminal side of the recognition sequence serves to completely separate this sequence from the gelator and trigger gel formation. In 2012 we reported a highly selective and generalizable method for detecting protease activity based on this approach.^{6a} While this method is suitable for most serine and cysteine proteases, it is not suitable for aspartyl proteases and metalloproteinases because these enzymes require specific residues on both sides of the scissile bond. Targeting these enzymes is more challenging because the leftover peptide residues attached to the gelator scaffold can disrupt the gelation process,⁷ and as a consequence, a new gelator may need to be discovered for each enzyme.

© The Royal Society of Chemistry [year]

Correspondence to: Anne J. McNeil, ajmcneil@umich.edu; Matthew B. Soellner, soellner@med.umich.edu.

[†]Electronic Supplementary Information (ESI) available: synthetic procedures; peptide characterization; rheology data; gelation data; LC-MS data; control experiments. See DOI: 10.1039/b000000x/

We reasoned that an aminopeptidase, which nondiscriminately cleaves amino acids off the N-terminus of a peptide,⁸ could be used to remove the leftover (prime-side recognition) residues from the gelator scaffold (Scheme 1). As a consequence, the same gelator can be used for detecting any protease by simply varying the recognition sequence. Using this approach, we describe herein the development of selective assays for matrix metalloprotease-9 (MMP-9) and prostate specific antigen (PSA) using a single gelator scaffold and aminopeptidase M (AP-M). Aminopeptidase M (AP-M) was selected because it will remove residues from nearly every sequence of natural amino acids.⁸

The sensing scheme is comprised of three key components: a solubility factor (SF), recognition sequence, and gelator. The solubility factor⁹ increases the solubility and ensures that the recognition sequence is accessible to the target enzyme in solution. The solubility factor also prevents premature cleavage of the substrate by AP-M because it contains a non-natural oligoethylene glycol unit at the N-terminus that is not recognized by AP-M. The recognition sequence contains a short peptide segment that is easily interchangeable and optimized for each target enzyme. Once this sequence is cleaved by the protease, the AP-M will non-discriminately cleave the remaining residues. To prevent the AP-M from cleaving the peptide-based gelator, a non-natural *p*-aminobenzamide (PABA) unit was included at the N-terminus. Gelator **1**^{6a} was selected for these studies because it forms stable gels in buffer (50 mM HEPES, 200 mM NaCl, 10 mM CaCl₂, 7.5% DMSO, pH = 7.5) with a low critical gel concentration (cgc, 1.7 mM).

We first targeted MMP-9¹⁰ because it has stringent requirements about which residues are present on both sides of the cleavage site,¹¹ and it has been implicated in several pathological conditions, including cancer metastasis¹² and arthritis.¹³ A scaffold containing an optimized recognition sequence for MMP-9 (GPKG-LKGA)¹⁴ was treated with both MMP-9 and AP-M in buffer. Gratifyingly, a stable gel was observed within 7 h (Figures 1A and S10). The importance of prime side residues was demonstrated when a recognition sequence lacking these residues showed no conversion over the same time (Figures 1B and S10).

Because, in principle, the assay depends on the concentration and activity of both enzymes, identifying conditions wherein the target enzyme (MMP-9) is rate-limiting is desired, ensuring a low detection limit for the target enzyme. LC-MS studies were used to monitor conversion of LKGA-**1** to **1** mediated by AP-M over time. These studies revealed that approximately 45% conversion is reached within 160 min, at which point gelation occurs

(ESI Figure S17). This rate is significantly faster than the 7 h needed for conversion of parent scaffold: SF-GPKG-LKGA-1 (ESI Figure S10). Thus, the rate-limiting step must be the initial MMP-9 triggered cleavage. Overall, the detection limit is 50 nM under these optimized conditions, which is within the levels present in cancer patients with elevated levels of circulating MMP-9 (71 ± 60 nM for non-small cell lung cancer patients, 36 ± 13 nM for healthy subjects).¹⁵ This suggests that our MMP-9 sensing gelator could readily discriminate between healthy patients and patients with aggressive cancers.

To demonstrate the generality of this approach, we targeted a different protease: prostate-specific antigen (PSA). PSA is a serine protease, however, it was selected because the prime side residues have a dramatic influence over the reactivity.¹⁶ In addition, PSA is an important biomarker for prostate cancer.¹⁷ Although overexpression of active PSA correlates with cancer prognosis, current screening methods measure total PSA concentration, not the fraction that is active.¹⁸ While total PSA levels as a prostate cancer diagnostic is controversial,^{18a} recent studies have demonstrated that active PSA enzyme in the blood is highly correlative to aggressive prostate cancer.¹⁹ Hence, an assay based on activity is highly desirable. A substrate containing an optimized PSA recognition sequence (HSAKFY-SG)^{16a} was synthesized and treated with PSA and AP-M in buffer. Within 24 h, a stable gel was formed (ESI Figure S14). A control experiment lacking PSA showed no gelation over the same time (ESI Figure S14). Similarly, if the prime side residues were missing (HSAKFY) from the substrate, no reaction was observed by LC-MS even after 24 h (ESI Figure S13).

Because PSA activity is rate-limiting, we hypothesized that the response time could be shortened by adding the cleaved substrate (SG-1) to the reaction mixture. Although SG-1 was largely insoluble, adding a lysine (i.e., SGK-1) significantly improved its solubility. This substrate is rapidly converted to 1 *in situ* using AP-M. Gratifyingly, including SGK-1 (1 mM) reduced the time-to-gelation from 24 h to 7.5 h (Figure 2). The detection limit of this PSA sensor is 32 nM of active enzyme, which is above the physiological levels of active PSA found in the blood of prostate cancer patients (~0.1 nM active enzyme).²⁰ However, high levels of active PSA are found in the extracellular fluid of prostate cancers (1.8 μ M).^{18b} On this basis, our PSA sensing gelator could be used as an aid in biopsy diagnosis. Our detection limit must be lowered considerably to be useful as a diagnostic for measuring active PSA levels in blood.²⁰ In principle, a lower detection limit can be achieved if a gelator with a lower cgc is used. Alternatively, a different recognition sequence with higher activity towards PSA would lead to lower detection limits. Additionally, patients with prostate cancer have high levels of proPSA, an inactive precursor of PSA, that could be converted into active PSA *in situ* (~30 nM proPSA, compared to less than 1 nM for healthy individuals)²⁰ using an additional enzyme.²¹

In summary, a generalizable method for detecting protease activity using gelation is described. We demonstrated that aminopeptidase M, which nondiscriminately cleaves amino acids off the N-terminus of a peptide, can be used to remove the residual components of a recognition sequence from the gel scaffold. As a consequence, the same gelator can be used to detect different proteases by simply switching the recognition sequences. Using this approach, we were able to detect both MMP-9 and PSA at physiological concentrations.

Given that these proteases are validated biomarkers for cancer, we believe that with further development this simple visual assay may be useful for early detection. Our future efforts will focus on accelerating the time for gelation by employing additives (i.e., growth promoters),²² designing alternative gelators with lower critical gel concentrations, and improving the activity of the recognition sequences. Overall, the system described herein is significantly more versatile than other enzyme-triggered gelations in the literature. As a result, we anticipate that this method will be utilized for the detection and diagnosis of other disease-relevant proteases.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Maureen Corrielus for help with peptide synthesis of PSA substrates. We thank the Arnold and Mabel Beckman Foundation (Young Investigator Award to A.J.M.) and National Institutes of Health (R00RR024366 to M.B.S.) for support of this work.

Notes and references

1. For recent reviews, see: Kim SB, Hattori M, Ozawa T. *Int J Mol Sci.* 2012; 13:16986–17005. [PubMed: 23235326] Razgulin A, Ma N, Rao J. *Chem Soc Rev.* 2011; 40:4186–4216. [PubMed: 21552609]
2. For recent reviews, see: Tang D, Cui Y, Chen G. *Analyst.* 2013; 138:981–990. [PubMed: 23304696] Xie X, Xu W, Liu X. *Acc Chem Res.* 2012; 45:1511–1520. [PubMed: 22786666] Tallury P, Malhotra A, Byrne LM, Santra S. *Adv Drug Deliv Rev.* 2010; 62:424–437. [PubMed: 19931579]
3. For recent reviews, see: Zhang Y, Kuang Y, Gao Y, Xu B. *Langmuir.* 2011; 27:529–537. [PubMed: 20608718] Williams RJ, Mart RJ, Ulijn RV. *Biopolymers.* 2010; 94:107–117. [PubMed: 20091879] Gao Y, Yang Z, Kuang Y, Ma ML, Li J, Zhao F, Xu B. *Biopolymers.* 2010; 94:19–31. [PubMed: 20091873]
4. Yang Z, Gu H, Fu D, Gao P, Lam JK, Xu B. *Adv Mater.* 2004; 16:1440–1444.
5. For recent examples, see: Li J, Gao Y, Kuang Y, Shi J, Du X, Zhou J, Wang H, Yang Z, Xu B. *J Am Chem Soc.* 2013; 135:9907–9914. [PubMed: 23742714] Guilbaud JB, Rochas C, Miller AF, Saiani A. *Biomacromolecules.* 2013; 14:1403–1411. [PubMed: 23506527] Hughes M, Birchall LS, Zuberi K, Aitken LA, Debnath S, Javid N, Ulijn RV. *Soft Matter.* 2012; 8:11565–11574. Williams RJ, Hall TE, Glattauer V, White J, Pasic PJ, Sorensen AB, Waddington L, McLean KM, Currie PD, Hartley PG. *Biomaterials.* 2011; 32:5304–5310. [PubMed: 21531457] Webber MJ, Newcomb CJ, Bitton R, Stupp SI. *Soft Matter.* 2011; 7:9665–9672. [PubMed: 22408645]
6. Few systems are selective for a single enzyme. For reference, see: Bremmer SC, Chen J, McNeil AJ, Soellner MB. *Chem Commun.* 2012; 48:5482–5484. Koda D, Maruyama T, Minakuchi N, Nakashima K, Goto M. *Chem Commun.* 2010; 46:979–981. Yang Z, Ho PL, Liang G, Chow KH, Wang Q, Cao Y, Guo Z, Xu B. *J Am Chem Soc.* 2007; 129:266–267. [PubMed: 17212393]
7. Seemingly minor structural changes can convert peptide-based gelators into nongelators. For recent examples, see: Houton KA, Morris KL, Chen L, Schmidtman M, Jones JTA, Serpell LC, Lloyd GO, Adams DJ. *Langmuir.* 2012; 28:9797–9806. [PubMed: 22651803] Muro-Small ML, Chen J, McNeil AJ. *Langmuir.* 2011; 27:13248–13253. [PubMed: 21958411] Wang H, Yang C, Tan M, Wang L, Kong D, Yang Z. *Soft Matter.* 2011; 7:3897–3905. Ryan DM, Doran TM, Anderson SB, Nilsson BL. *Langmuir.* 2011; 27:4029–4039. [PubMed: 21401045]
8. Drag M, Bogoy M, Ellman JA, Salvesen GS. *J Biol Chem.* 2009; 285:3310–3318. [PubMed: 19948737]
9. The solubility factor structure is as follows: PEG₄-Arg-Arg-Ser-Pro-.

10. For a related example of MMP-9 triggered gelation, see: Yang Z, Ma M, Xu B. *Soft Matter*. 2009; 5:2546–2548. The detection limit of this gelation system for MMP-9 is 168 nM, which is above the physiological levels of MMP-9.
11. Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S, Smith JW. *J Biol Chem*. 2001; 276:20572–20578. [PubMed: 11279151]
12. (a) Yu Q, Stamenkovic I. *Genes & Dev*. 1999; 13:35–48. [PubMed: 9887098] (b) Deryugina EI, Quigley JP. *Cancer Metast Rev*. 2006; 25:9–34.
13. Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, Arbeit LA. *Clin Immunol Immunopathol*. 1996; 78:161–171. [PubMed: 8625558]
14. Prudova A, Keller U, Butler GS, Overall CM. *Mol Cell Proteomics*. 2010; 9:894–911. [PubMed: 20305284]
15. Iizasa T, Fujisawa T, Suzuki M, Motohashi SI, Yasufuku K, Yasukawa T, Baba M, Shiba M. *Clin Cancer Res*. 1999; 5:149–153. [PubMed: 9918213]
16. (a) Coombs GS, Bergstrom RC, Pellequer JL, Baker SI, Navre M, Smith MM, Tainer JA, Madison EL, Corey DR. *Chem Biol*. 1998; 5:475–488. [PubMed: 9751643] (b) Debela M, Magdolen V, Schechter N, Valachova M, Lottspeich F, Craik CS, Choe Y, Bode W, Goettig P. *J Biol Chem*. 2006; 281:25678–25688. [PubMed: 16740631]
17. (a) Balk SP, Ko YJ, Bubey GJ. *J Clin Oncology*. 2003; 21:383–391. (b) LeBeau AM, Kostova M, Craik CS, Denmeade SR. *Biol Chem*. 2010; 391:333–343. [PubMed: 20180648]
18. For a recent review on PSA screening: Lilja J, Ulmert D, Vickers AJ. *Nat Reviews Cancer*. 2008; 8:268–278. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. *The Prostate*. 2001; 48:1–6. [PubMed: 11391681]
19. (a) Wu P, Zhu L, Stenman UH, Leinonen J. *Clin Chem*. 2004; 50:125–129. [PubMed: 14633910] (b) Wu P, Stenman UH, Pakkala M, Narvanen A, Leinonen J. *Prostate*. 2004; 58:345–353. [PubMed: 14968435]
20. Niemela P, Lovgren J, Karp M, Lilja H, Pettersson K. *Clin Chem*. 2002; 48:1257–1264. [PubMed: 12142382]
21. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K. *Biochemistry*. 2001; 40:15341–15348. [PubMed: 11735417]
22. Adhia YJ, Schloemer TH, Perez MT, McNeil AJ. *Soft Matter*. 2012; 8:430–434.

Figure 1.

(A) An opaque gel was observed within 7 h of adding MMP-9 (50 nM) to a buffer solution containing AP-M (1.2 μ M) and the gelator scaffold with the optimized recognition sequence. (B) No gel was observed when the prime side residues were not included under otherwise identical conditions. Pictures were taken after 24 h.

Figure 2.

(A) An opaque gel was observed within 7.5 h when PSA (1.6 μM) was added to a buffer solution containing AP-M (1.2 μM), SGK-1 (1 mM) and the gelator scaffold with the optimized recognition sequence. No gel was observed when either (B) AP-M or (C) PSA was excluded, under otherwise identical conditions.

Scheme 1.

General design strategy for detecting proteases via gelation using recognition sequences and aminopeptidase M.